356 related articles for article (PubMed ID: 20981527)
1. Fragment-based drug design.
Feyfant E; Cross JB; Paris K; Tsao DH
Methods Mol Biol; 2011; 685():241-52. PubMed ID: 20981527
[TBL] [Abstract][Full Text] [Related]
2. Effective progression of nuclear magnetic resonance-detected fragment hits.
Eaton HL; Wyss DF
Methods Enzymol; 2011; 493():447-68. PubMed ID: 21371601
[TBL] [Abstract][Full Text] [Related]
3. Design of screening collections for successful fragment-based lead discovery.
Na J; Hu Q
Methods Mol Biol; 2011; 685():219-40. PubMed ID: 20981526
[TBL] [Abstract][Full Text] [Related]
4. Design and implementation of an ribonucleic acid (RNA) directed fragment library.
Bodoor K; Boyapati V; Gopu V; Boisdore M; Allam K; Miller J; Treleaven WD; Weldeghiorghis T; Aboul-ela F
J Med Chem; 2009 Jun; 52(12):3753-61. PubMed ID: 19445516
[TBL] [Abstract][Full Text] [Related]
5. Two 'Golden Ratio' indices in fragment-based drug discovery.
Orita M; Ohno K; Niimi T
Drug Discov Today; 2009 Mar; 14(5-6):321-8. PubMed ID: 19028598
[TBL] [Abstract][Full Text] [Related]
6. Fragment-based drug discovery using rational design.
Jhoti H
Ernst Schering Found Symp Proc; 2007; (3):169-85. PubMed ID: 18510103
[TBL] [Abstract][Full Text] [Related]
7. Structure-guided fragment screening for lead discovery.
Verdonk ML; Hartshorn MJ
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):404-10. PubMed ID: 15338949
[TBL] [Abstract][Full Text] [Related]
8. Efficiency of hit generation and structural characterization in fragment-based ligand discovery.
Larsson A; Jansson A; Åberg A; Nordlund P
Curr Opin Chem Biol; 2011 Aug; 15(4):482-8. PubMed ID: 21724447
[TBL] [Abstract][Full Text] [Related]
9. Electron density guided fragment-based drug design--a lead generation example.
Abad MC; Gibbs AC; Zhang X
Methods Enzymol; 2011; 493():487-508. PubMed ID: 21371603
[TBL] [Abstract][Full Text] [Related]
10. Lead generation and examples opinion regarding how to follow up hits.
Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
[TBL] [Abstract][Full Text] [Related]
11. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
Giannetti AM
Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
[TBL] [Abstract][Full Text] [Related]
12. Designing a diverse high-quality library for crystallography-based FBDD screening.
Tounge BA; Parker MH
Methods Enzymol; 2011; 493():3-20. PubMed ID: 21371585
[TBL] [Abstract][Full Text] [Related]
13. Introduction to fragment-based drug discovery.
Erlanson DA
Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
[TBL] [Abstract][Full Text] [Related]
14. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
[TBL] [Abstract][Full Text] [Related]
15. Fragment informatics and computational fragment-based drug design: an overview and update.
Sheng C; Zhang W
Med Res Rev; 2013 May; 33(3):554-98. PubMed ID: 22430881
[TBL] [Abstract][Full Text] [Related]
16. Counting on Fragment Based Drug Design Approach for Drug Discovery.
Kashyap A; Singh PK; Silakari O
Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
[TBL] [Abstract][Full Text] [Related]
17. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
Maurer T
Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
[TBL] [Abstract][Full Text] [Related]
18. Medicinal chemistry inspired fragment-based drug discovery.
Lanter J; Zhang X; Sui Z
Methods Enzymol; 2011; 493():421-45. PubMed ID: 21371600
[TBL] [Abstract][Full Text] [Related]
19. In silico fragment-based drug design.
Konteatis ZD
Expert Opin Drug Discov; 2010 Nov; 5(11):1047-65. PubMed ID: 22827744
[TBL] [Abstract][Full Text] [Related]
20. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.
Wang YS; Strickland C; Voigt JH; Kennedy ME; Beyer BM; Senior MM; Smith EM; Nechuta TL; Madison VS; Czarniecki M; McKittrick BA; Stamford AW; Parker EM; Hunter JC; Greenlee WJ; Wyss DF
J Med Chem; 2010 Feb; 53(3):942-50. PubMed ID: 20043700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
